Date: June 15th, 2018
Source: Office of Scientific R&D, Jinan University

The China Food and Drug Administration has approved clinical drug trials for eye drops developed by a research team led by Prof. Huang Yadong of JNU's Biopharmaceutical Research Institute in cooperation with Prof. Li Xiaokun's team from Wenzhou Medical University. The new biological preparation of Class I-Recombinant Human Keratinocyte Growth Factor-2 (rhKGF-2) Eye Drops is resulted from 10 years of research by a team including Qu Hongyan, Xiong Sheng, Xiang Qi, Hu Hao, Su Zhijian and Zhang Qihao of JNU. The clinical approval number is 2018L02329.

(The document of approval for new drug clinical trial)

(Relevant products)

Corneal injury occurs frequently in ophthalmology. KGF-2 eye drops can accelerate healing, inhibit corneal neovascularization, reduce scarring and improve corneal transparency. Once on the market, the eye drops will not only help repairing corneal injury but also represent a breakthrough in the field.

The approval of the clinical trial by CFDA is an early result of JNU's construction as a Double First-Class and high-level university. It is also a major achievement in promoting the marketing of scientific and technological results, as well as accelerating innovation in pharmaceutical research and developing JNU's National Engineering Research Center of Genetic Pharmaceuticals. The success of the eye drops project demonstrates that the center has reached a leading level in innovative pharmaceuticals research and development.

This study has been supported by the National Major Scientific and Technological Special Project for Significant New Drugs Development; the Special Project on the Integration of Industry, Education and Research of Guangdong; the Key Technologies Research and Development Program of Guangzhou; and the Small and Medium Enterprise Technology Innovation Fund. The rhKGF-2 eye drops have already received three patents.